________
Source: Investopedia
By ALAN FARLEY | October 1, 2020
AstraZeneca PLC (AZN) is developing Europe's top COVID-19 vaccine candidate and has resumed Phase 3 trials in many countries after a U.K. patient reportedly suffered a "serious adverse reaction." The United States is a notable exception, with the Food and Drug Administration (FDA) continuing a halt while it widens the scope of an investigation. Unfortunately, politics can't be ruled out, because any delays could benefit American vaccine candidates.
The European Medicines Agency (EMA) has just begun a "rolling review" of the trial, meaning it is taking a look at the first batch of data. This approach is used to speed up the approval process but may also benefit the European Union's competitiveness in getting a profitable drug to market. Still, it will take "weeks and months" to analyze and evaluate ongoing large-scale clinical trials, especially if new adverse reactions are reported.
Pfizer CEO pushes back against Trump claim on vaccine timing
Robert Kennedy Jr.: CDC Is A Privately Owned Vaccine Company
By ALAN FARLEY | October 1, 2020
AstraZeneca PLC (AZN) is developing Europe's top COVID-19 vaccine candidate and has resumed Phase 3 trials in many countries after a U.K. patient reportedly suffered a "serious adverse reaction." The United States is a notable exception, with the Food and Drug Administration (FDA) continuing a halt while it widens the scope of an investigation. Unfortunately, politics can't be ruled out, because any delays could benefit American vaccine candidates.
The European Medicines Agency (EMA) has just begun a "rolling review" of the trial, meaning it is taking a look at the first batch of data. This approach is used to speed up the approval process but may also benefit the European Union's competitiveness in getting a profitable drug to market. Still, it will take "weeks and months" to analyze and evaluate ongoing large-scale clinical trials, especially if new adverse reactions are reported.
AstraZeneca stock has struggled since popping to an all-time high in the $60s in July, with heavy selling pressure indicating that speculators are walking away in favor of other pharmaceutical companies. In addition, AstraZeneca is already one of the world's biggest drug companies, with valuation levered to a broad pipeline rather than hopes of hitting the COVID jackpot. Even so, good news should reawaken buying interest, potentially adding 15% to 20% to the current stock price.
AstraZeneca is covered by just four Wall Street analysts, with the entire quartet posting "Buy" ratings. Price targets range from a low of $61 to a Street-high $121, while the stock opened Thursday's session $5 below the low target and $65 below the high target. This humble placement should support much higher prices, but potential shareholders shouldn't dismiss unusually weak buying interest, which probably reflects lesser-known headwinds.
Please go to Investopedia to read the entire article.
Related:
AstraZeneca bolsters Covid-19 vaccine supply with new deal
Japan to offer free coronavirus vaccinations to all citizens
AstraZeneca is covered by just four Wall Street analysts, with the entire quartet posting "Buy" ratings. Price targets range from a low of $61 to a Street-high $121, while the stock opened Thursday's session $5 below the low target and $65 below the high target. This humble placement should support much higher prices, but potential shareholders shouldn't dismiss unusually weak buying interest, which probably reflects lesser-known headwinds.
Please go to Investopedia to read the entire article.
________
Ed.'s note: The UK's Johnson here is a salesmen tossing out the pitch for the UK's AstraZeneca COVID vaccine (injectable). Just like Prince Andrew was in Saudi Arabia selling UK's weapons systems some years ago. Listen carefully as Johnson here sells you the idea to once again with these commercial salesmen, to "trust the science." Do you want to participate in this system of commerce? Do you know and fully grasp what system you are operating in under law? Public or private? You are simply going to turn over to big tech and big Pharma your acceptance of their science to "make the world a more benign and better place?" A politician especially from the British empire is telling you the "world will become a more benign place." What do you think? Johnson tells us to "trust the science" and look back on how vaccines "saved children from polio." Really, Johnson, well what about the Gates-funded vaccine in Africa that caused a polio outbreak? The Africans no longer appreciate being the vaccine guinea pigs.
Related:
AstraZeneca took out $3 billion worth of bonds to cover the production of the COVID vaccine. Watch closely what these governments will do. As soon as the vast portion of the population are injected, the COVID operation will disappear, investors are happy and bonds paid off.
Pfizer the US competitor. Didn't Johnson above say to "trust the science?" Pfizer's CEO said it won't bend to pressure to develop a COVID vaccine. Sounds like good PR to us. When billions are riding on a vaccine Pfizer won't bend to pressure. Sure thing.
The CDC comes in registered as a private corporation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.